Harley-Davidson misses second-quarter profit estimates as tariffs weigh
However, shares of the company rose as much as 12% in premarket trading after the company said that it would offload loans from its financial unit to KKR and PIMCO valued at over $5 billion.
Leisure vehicle demand has been on a decline in the U.S., with consumers rethinking non-essential purchases in an uncertain economy.
Harley's sales have also taken a hit over the years as its bikes struggle to resonate with younger riders, who are looking for fuel efficient models instead with modern safety features.
"Given that the global tariff and business outlook especially for discretionary product purchases remains uncertain, we continue to withhold our full year HDMC (Harley Davidson Motorcycle Company) 2025 financial outlook," Harley-Davidson said.
Between February and now, close to 100 U.S. companies have either withdrawn or cut their guidance as uncertainty over tariffs throws financial planning out of gear, with most of them from the consumer and automotive and transportation sectors, according to Reuters calculations.
Harley-Davidson's profit fell to $108 million, or 88 cents per share, in the second quarter from $218 million, or $1.63 per share, a year earlier.
Analysts on average had expected a profit of 96 cents per share, according to data compiled by LSEG.
Overall revenue in the quarter fell 19% to $1.3 billion.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Job market concerns take center stage as earnings season rolls on: What to watch this week
Stocks tumbled from record highs on Friday as data revealed the US labor market is not on as solid footing as previously thought. On the week, the S&P 500 (^GSPC) fell nearly 2.4%, while the Nasdaq Composite (^IXIC) slid 2.2% and the Dow Jones Industrial Average (^DJI) shed 1.2%. Markets will be greeted with a quieter week of economic news with no major releases anticipated. Meanwhile, another busy week of corporate releases is set to greet investors with 122 S&P 500 companies set to report, led by Palantir (PLTR), Eli Lilly (LLY), and Disney (DIS). A September shift Markets exited Wednesday's Federal Reserve press conference leaning toward no interest rate cuts in the near future. That narrative flipped on its head on Friday morning. The latest monthly jobs report showed the US labor market added fewer jobs than expected in July while the unemployment rate moved higher, and revisions to prior months' numbers revealed significantly fewer jobs had been added than initially thought. In its release, the BLS said downward revisions to the May and June jobs reports "were larger than normal," with those changes showing more than a quarter million fewer jobs were added to the economy over those months. May's job gains were revised down to 19,000 from 144,000, while June's additions were cut to just 14,000 from the 147,000 initially reported. Market pricing and economists argue Friday's report was likely a game changer for the overall economic narrative and how the Fed will move forward. Following Friday's jobs report, the probability of a September interest rate cut from the Fed surged to 83%, up from just 38% the day prior, per the CME FedWatch Tool. "Our base case since January has been that the Fed won't cut rates this year," Bank of America Securities US economist Shruti Mishra wrote in a note to clients. "However, we have been arguing that the most likely alternate scenario is that labor market deterioration will force the Fed into 'bad cuts', which could play out at a pace of at least 25bp per meeting. The massive downward revision to payrolls in the July jobs report increases the probability of this scenario." AI leadership The July jobs report showed the US economy may be slowing more than initially thought, sparking a Friday market sell-off. "Ultimately, stocks do better in a stronger economy than one that requires the intervention from the Fed," Interactive Brokers chief strategist Steve Sosnick told Yahoo Finance. The economic growth concerns clouded what had been a positive week for the market as Big Tech earnings revealed AI investment is not stopping anytime soon. In at note to clients on Friday, Capital Economics senior market economist James Reilly wrote that Friday's market-sell off is likely "overdone," as AI will remain the "key driver" of global equities. "These major US 'hyperscalers' are collectively continuing to invest heavily," Reilly wrote while pointing out Big Tech has recently outperformed the broader market following earnings reports. "That's one reason why we are positive on the outlook for the tech-heavy segments of the stock market, and on the outlook for US stocks as a whole." Earnings volatility After about two-thirds of the S&P 500 have reported earnings, the index is pacing for earnings growth of 10.3%, up from the 5% expected on June 27, per FactSet data. Largely, the market has floated higher amid the slew of earnings releases. But under the surface, there have been significant stock moves off individual reports. In just the past week, Meta (META) stock rose more than 12% after topping estimates for both revenue and earnings per share. Meanwhile, Novo Nordisk (NVO) stock tanked 20% after cutting its full-year sales outlook. Julian Emanuel, who leads the equity, derivatives, and quantitative strategy team at Evercore ISI, noted that stocks are moving more than average in the day following releases, regardless of whether or not they beat or miss Wall Street's expectations. For example, the average S&P 500 stock that misses estimates for both sales and earnings per share is seeing a 4.9% decline in the next trading day, a steeper decline than the average of 3.2% seen over the past five years. With the market trading near record highs, Emanuel noted investors are "agitated by anything short of perfect" this corporate earnings season. Weekly Calendar Monday Economic data: Factory orders, June (-5% expected, +8.2% prior); Durable goods orders, June final (-9.3% expected, -9.3% prior) Earnings: Hims & Hers (HIMS), Palantir (PLTR), Tyson (TSN), Wayfair (W) Tuesday Economic data: S&P Global US Services PMI, July final (55.2 prior), S&P Global US Composite, July final (54.6 prior); ISM services index, July (51.5 expected, 50.8 prior) Earnings: AMD (AMD), BP (BP), Caterpillar (CAT), Duke Energy (DUK), Lucid Group (LCID), Opendoor (OPEN), Pfizer (PFE), Rivian (RIVN), Super Micro Computer (SMCI), Snap (SNAP), Upstart (UPST) Wednesday Economic data: MBA mortgage applications, week ending Aug. 1 (-3.8% prior) Earnings: Applovin (APP), e.l.f. Beauty (ELF), Disney (DIS), DraftKings (DKNG), McDonald's (MCD), Novo Nordisk (NVO), Shopify (SHOP), Six Flags (FUN), Uber (UBER) Thursday Economic data: Initial jobless claims, week ending Aug. 2 (218,000 prior); Nonfarm productivity, second quarter preliminary (+2.5% expected, -1.5% prior); Unit labor costs, second quarter preliminary (+1.3% expected, +6.6% prior) Earnings: Block (XYZ), Celsius (CELH), Conoco Phillips (COP), Eli Lilly (LLY), Sony (SONY), SoundHound (SOUN) (SOUN), Pinterest (PINS), Take Two Interactive (TTWO), Twilio (TWLO), The Trade Desk (TTD), Vistra Energy (VST) Friday Economic calendar: No notable releases. Earnings: Canopy Growth (CGC), fuboTV (FUBO), Wendy's (WEN) Josh Schafer is a reporter for Yahoo Finance. Follow him on X @_joshschafer. Sign in to access your portfolio
Associated Press
7 minutes ago
- Associated Press
SRPT LEGAL ALERT: Lose Money on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT)
NEW YORK, Aug. 03, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: Investors have until August 25, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Sarepta securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Dolgicer v. Sarepta Therapeutics, Inc., et al., No. 25-cv-05317. Why Was Sarepta Sued for Securities Fraud? Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta's most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. As alleged, Sarepta repeatedly touted the safety profile of Elevidys and told investors that the benefits of the treatment outweighed its risks. In truth, Elevidys causes fatal acute liver failure in some patients. The Stock Declines as the Truth Is Revealed On March 18, 2025, Sarepta announced that a patient that had been treated with Elevidys died after suffering acute liver failure. On this news, the price of Sarepta stock fell $27.81 per share, or over 27%, from $101.35 per share on March 17, 2025, to $73.54 per share on March 18, 2025. Nevertheless, on the same day, Sarepta assured investors that 'the benefit-risk of ELEVIDYS remains positive.' Next, on June 15, 2025, Sarepta announced that a second patient treated with Elevidys had died from acute liver failure and that it was suspending certain shipments of Elevidys and paused dosing in an ongoing clinical trial of the treatment. On this news, the price of Sarepta stock fell $15.24 per share, or more than 42%, from $36.18 per share on June 13, 2025, to $20.94 per share on June 16, 2025. Finally, on July 17, 2025, Sarepta revealed that a third patient treated with one of Sarepta's investigational treatments related to Elevidys had died from acute liver failure in June 2025. On this news, the price of Sarepta stock fell more than 40% on July 18, 2025. Click here for more information: What Can You Do? If you invested in Sarepta you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz [email protected] 212.789.3619 Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.
Fox News
7 minutes ago
- Fox News
Steel company CEO hints at US industry boom: The media is 'missing' what's happening
Marlin Steel CEO Drew Greenblatt reveals why now is an 'optimistic' time for U.S. factory workers and discusses President Donald Trump's potential to strike 'fabulous' deals with Mexico and Canada.
